aTyr Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATYR research report →
Range $1 – $17
Price Chart
About the company
aTyr Pharma, Inc. , a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions.
- CEO
- Sanjay S. Shukla
- IPO
- 2015
- Employees
- 58
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ATYR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.37M
- P/E
- -0.19
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.29
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.46%
- ROIC
- -125.04%
Latest fiscal year · YoY change
- Revenue
- $190.00K-19.1%
- Gross Profit
- $-1,363,000-680.0%
- Op Income
- $-77,627,000
- Net Income
- $-74,118,000-15.8%
- EPS
- $-32.00+7.0%
- OCF Growth
- +10.3%
- FCF Growth
- +10.3%
- 52W High
- $44.40
- 52W Low
- $3.69
- 50D MA
- $9.19
- 200D MA
- $22.42
- Beta
- 0.53
- RSI (14)
- 27
- Avg Volume
- 114.17K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
aTyr highlighted a clean Phase 3 sarcoidosis program, preserved cash runway, and reiterated confidence ahead of a third-quarter EFZO-FIT readout.· March 13, 2025
- EFZO-FIT enrollment is complete: 268 patients at 85 centers across 9 countries, with top-line Phase 3 data expected in the third quarter.
- FDA feedback changed the primary steroid endpoint from average dose during weeks 12-48 to absolute change from baseline to week 48; management said powering remains over 90%.
- Four DSMB reviews found no safety concerns and recommended no changes, reinforcing management’s view of efzofitimod’s safety profile.
- aTyr said its market research suggests more diagnosed sarcoidosis patients with lung involvement than previously estimated and strong payor interest in an on-label biologic with steroid reduction.
- Cash at year-end was $75.1 million, plus about $18.8 million raised after quarter-end via ATM; runway is now expected to extend through 1-year after the Phase 3 readout.
For 2024, collaboration and license revenue tied to the Kyorin agreement was $0.2 million. Research and development expense was $54.4 million and general and administrative expense was $13.8 million for the year ended 2024. The company ended 2024 with $75.1 million in cash, restricted cash, cash equivalents, and investments, and raised approximately $18.8 million in gross proceeds after quarter-end from its ATM program. Management said cash runway is expected to fund operations through 1-year following the Phase 3 EFZO-FIT readout, and some ATM proceeds will be used for commercial readiness. No quarterly revenue or EPS was reported on the call. Forward-looking timing includes EFZO-FIT top-line data in the third quarter and interim EFZO-CONNECT skin data in the second quarter.
Sanjay Shukla framed 2024 as a pivotal year because the company completed enrollment in what he called the largest interventional pulmonary sarcoidosis study ever conducted. He emphasized that the FDA-aligned endpoint clarification simplifies the analysis without changing the study’s over-90% power, and he repeatedly returned to confidence in efzofitimod’s safety, durability, and commercial potential. His tone was highly upbeat, with strong emphasis on regulatory discipline, market opportunity, and the possibility of a transformative sarcoidosis outcome later this year.
Jill Broadfoot focused on liquidity, spend, and runway. She said year-end cash, restricted cash, cash equivalents, and investments totaled $75.1 million, and the company raised about $18.8 million in gross proceeds via the ATM after quarter-end. She cited full-year 2024 R&D of $54.4 million and G&A of $13.8 million, and said the updated runway guidance now covers operations through one year after the Phase 3 EFZO-FIT readout, with some ATM proceeds earmarked for commercial readiness and launch preparation.
Analyst questions concentrated on the FDA-driven statistical plan change, the expanded access program, and whether the new endpoint could affect trial interpretation. Management said the change was mainly about simplification and pre-specification, with no change to the study’s power, and noted that a trailing 28-day view helps handle patients who are still tapering near week 48. On the EAP, management would not estimate a participation percentage, saying uptake is site- and country-dependent, but described interest as robust and emphasized that patients and investigators remain blinded to treatment assignment. Questions also probed the Phase 2 steroid reduction data, FEV1’s role, and the scleroderma interim readout; management said FEV1 was discussed little with the FDA and that the upcoming scleroderma skin data are mainly meant to learn about biology, not to read through directly to sarcoidosis.
The call reinforced that efzofitimod has multiple upcoming catalysts: ATS baseline data in May, EFZO-CONNECT interim skin data in the second quarter, and pivotal EFZO-FIT data in the third quarter. Management pointed to four clean DSMB reviews, a peer-reviewed Science Translational Medicine publication on mechanism, and payor research suggesting willingness to reimburse an on-label biologic in sarcoidosis. The company also said its cash runway now extends through one year after the readout, reducing near-term financing pressure.
The biggest risk remains that the Phase 3 readout does not confirm the earlier signal, especially since management acknowledged the new endpoint change is meant to simplify analysis rather than prove efficacy. The EAP and durability comments were encouraging but remained anecdotal and blinded, so they do not substitute for trial data. Management also noted that the scleroderma interim dataset will be small and limited to skin measures, with little read-through to the main sarcoidosis trial.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 2.45M
- Float Shares
- 2.45M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 30 ETFs
Biggest fund positions in ATYR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Yaras Brandon | other | 410,000 |
| Oct 1, 26 | Yaras Brandon | other | 0 |
| Oct 1, 26 | Yaras Brandon | other | 0 |
| Oct 1, 26 | Yaras Brandon | other | 0 |
| Oct 1, 26 | Yaras Brandon | other | 0 |
| Oct 1, 26 | Yaras Brandon | other | 0 |
| May 27, 26 | SCHIMMEL PAUL | buy | 100,000 |
| May 11, 26 | Coughlin Timothy | other | 50,000 |
| May 11, 26 | BENEVICH ERIC | other | 50,000 |
| May 11, 26 | Gross Jane A | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATYR coverage
Recent articles, reports, and earnings notes.
No research on ATYR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATYR report →aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
globenewswire.com · Nov 19
aTyr Pharma to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 11
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
globenewswire.com · Oct 29
aTyr Pharma Announces One-for-40 Reverse Stock Split
globenewswire.com · Oct 27
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
globenewswire.com · Oct 19
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
globenewswire.com · Oct 13
Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)
defenseworld.net · Sep 30
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
benzinga.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.